Tuesday, October 26, 2004

Vasogen's VP025 in the news.

Vasogen is working on VP025, a drug that delays the onset of ALS. Here are two PR stories about it:
  1. Vasogen's VP025 Delays Disease Onset and Prolongs Survival in Preclinical ALS (Lou Gehrig's disease) Model
  2. ALS Researchers Deliver Oral Presentation of Vasogen's VP025 at Neuroscience 2004
I'd like to be hopeful about the progress being made on these treatments, but to be honest, my hopes for treatment are much higher than "delay the onset."
Post a Comment